Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EUR-1008 Microtabs in pediatric CF with EPI
NCT00981214Phase 3Completed
- Sponsor
- Forest Laboratories
- Start
- May 2006
- Primary completion
- Sep 2006
- Modality
- Replacement Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of pancreatin in exocrine pancreatic insufficiency (EPI), sponsored by Forest Laboratories. Primary endpoint: Percentage of Participants Who Were Responders at Day 18. Started May 2006; status: completed.
02
Drugs
pancreatin
03
Conditions
exocrine pancreatic insufficiency (EPI)
Beyond the preview
Go deeper on NCT00981214.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00981214.